Literature DB >> 18663085

Apolipoprotein CIII links hyperlipidemia with vascular endothelial cell dysfunction.

Akio Kawakami1, Mizuko Osaka, Mariko Tani, Hiroshi Azuma, Frank M Sacks, Kentaro Shimokado, Masayuki Yoshida.   

Abstract

BACKGROUND: Apolipoprotein CIII (apoCIII) is a component of some triglyceride-rich very-low-density and low-density lipoprotein and is elevated in dyslipidemia with insulin resistance and the metabolic syndrome. We previously reported that apoCIII directly activates proinflammatory and atherogenic signaling in vascular endothelial cells through protein kinase C-beta (PKCbeta). Because PKCbeta impairs the response of vascular endothelial cells to insulin, we tested the hypothesis that apoCIII affects insulin signaling in vascular endothelial cells and its function in vitro and in vivo. METHODS AND
RESULTS: ApoCIII inhibited insulin-induced tyrosine phosphorylation of insulin receptor substrate 1 (IRS-1), decreasing phosphatidylinositol 3-kinase (PI3K)/Akt activation in human umbilical vein endothelial cells. These effects of apoCIII led to reduced endothelial nitric oxide synthase (eNOS) activation and NO release into the media. ApoCIII activated PKCbeta in human umbilical vein endothelial cells, resulting in IRS-1 dysfunction via serine phosphorylation. ApoCIII also activated mitogen-activated protein kinase through PKCbeta. The impaired insulin signaling was restored by PKCbeta inhibitor or MEK1 inhibitor. ApoCIII-rich very-low-density lipoprotein and apoCIII impaired insulin signaling in the aorta of C57BL/6J mice and in human umbilical vein endothelial cells, which was recovered by PKCbeta inhibitor. They also inhibited endothelium-dependent relaxation of the aortas of C57BL/6J mice. In summary, apoCIII in very-low-density lipoprotein impaired insulin stimulation of NO production by vascular endothelium and induced endothelial dysfunction in vivo. This adverse effect of apoCIII was mediated by its activation of PKCbeta, which inhibits the IRS-1/PI3K/Akt/eNOS pathway.
CONCLUSIONS: Our results suggest that apoCIII is a crucial link between dyslipidemia and insulin resistance in vascular endothelial cells with consequential deleterious effects on their atheroprotective functions.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18663085     DOI: 10.1161/CIRCULATIONAHA.108.784785

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  27 in total

1.  Carotid Artery Intima-Media Thickness in Young Adults with Family History of Coronary Artery Disease.

Authors:  Kanimozhi Sadasivam; Poornima Nagarajan; Indira Durai; Meenakshi Sundari; Saravanan Ayyavoo; Thilagavathi Ramamoorthy
Journal:  J Clin Diagn Res       Date:  2015-09-01

2.  Complexities of plasma apolipoprotein C-III metabolism.

Authors:  Frank M Sacks; Chunyu Zheng; Jeffrey S Cohn
Journal:  J Lipid Res       Date:  2011-03-18       Impact factor: 5.922

3.  Dietary Palmitoleic Acid Attenuates Atherosclerosis Progression and Hyperlipidemia in Low-Density Lipoprotein Receptor-Deficient Mice.

Authors:  Zhi-Hong Yang; Milton Pryor; Audrey Noguchi; Maureen Sampson; Brittany Johnson; Matthew Pryor; Kwame Donkor; Marcelo Amar; Alan T Remaley
Journal:  Mol Nutr Food Res       Date:  2019-04-10       Impact factor: 5.914

4.  Low-density lipoproteins containing apolipoprotein C-III and the risk of coronary heart disease.

Authors:  Carlos O Mendivil; Eric B Rimm; Jeremy Furtado; Stephanie E Chiuve; Frank M Sacks
Journal:  Circulation       Date:  2011-10-10       Impact factor: 29.690

5.  Apolipoprotein C-III and the metabolic basis for hypertriglyceridemia and the dense low-density lipoprotein phenotype.

Authors:  Chunyu Zheng; Christina Khoo; Jeremy Furtado; Frank M Sacks
Journal:  Circulation       Date:  2010-04-05       Impact factor: 29.690

Review 6.  Phenotypes and genotypes of high density lipoprotein cholesterol in exceptional longevity.

Authors:  Sofiya Milman; Gil Atzmon; Jill Crandall; Nir Barzilai
Journal:  Curr Vasc Pharmacol       Date:  2014       Impact factor: 2.719

7.  Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease.

Authors:  Christian Besler; Kathrin Heinrich; Lucia Rohrer; Carola Doerries; Meliana Riwanto; Diana M Shih; Angeliki Chroni; Keiko Yonekawa; Sokrates Stein; Nicola Schaefer; Maja Mueller; Alexander Akhmedov; Georgios Daniil; Costantina Manes; Christian Templin; Christophe Wyss; Willibald Maier; Felix C Tanner; Christian M Matter; Roberto Corti; Clement Furlong; Aldons J Lusis; Arnold von Eckardstein; Alan M Fogelman; Thomas F Lüscher; Ulf Landmesser
Journal:  J Clin Invest       Date:  2011-06-23       Impact factor: 14.808

8.  Hypertriglyceridemia and delayed clearance of fat load in transgenic rabbits expressing human apolipoprotein CIII.

Authors:  Yinyuan Ding; Yuhui Wang; Hong Zhu; Jianglin Fan; Liqing Yu; George Liu; Enqi Liu
Journal:  Transgenic Res       Date:  2010-12-01       Impact factor: 2.788

Review 9.  The role of triglycerides in atherosclerosis.

Authors:  Beatriz G Talayero; Frank M Sacks
Journal:  Curr Cardiol Rep       Date:  2011-12       Impact factor: 2.931

10.  Chemical composition-oriented receptor selectivity of L5, a naturally occurring atherogenic low-density lipoprotein.

Authors:  Liang-Yin Ke; David A Engler; Jonathan Lu; Risë K Matsunami; Hua-Chen Chan; Guei-Jane Wang; Chao-Yuh Yang; Jan-Gowth Chang; Chu-Huang Chen
Journal:  Pure Appl Chem       Date:  2011       Impact factor: 2.453

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.